指南与共识神经康复

卒中康复生物标志物:卒中康复圆桌会议共识核心推荐

Biomarkers of Stroke Recovery: Consensus-Based Core Recommendations from the Stroke Recovery and Rehabilitation Roundtable.
指南 / 共识 · Neurorehabil Neural Repair · 2017-01-01

本文为卒中康复与康复圆桌会议的共识声明,聚焦运动、感觉、认知和语言域的生物标志物,基于脑结构与功能证据而非血液与遗传标志物。文章区分了已可纳入临床试验的生物标志物与有前景但尚未成熟的标志物,并以示例说明生物标志物如何提升康复研究。

要点

  • 生物标志物可区分卒中患者亚组,帮助回答恢复潜力和最佳康复策略两个临床难题。
  • 共识聚焦运动、感觉、认知和语言域的脑结构与功能标志物,排除血液和遗传标志物。
  • 已明确可纳入临床试验的标志物与有前景但未成熟的标志物,后者为发展优先方向。

核心结论

  • 开发生物标志物以区分患者亚组,有助于解决康复内容决策和研究中参与者异质性混合的问题。
  • 共识提供了卒中恢复生物标志物的当前证据状态,区分可纳入临床试验与尚需发展的标志物。
  • 纳入生物标志物可能增强未来临床试验,为推进卒中康复实践与研究指明方向。

研究设计与样本

  • 本文为卒中康复与康复圆桌会议的共识声明,基于当前证据总结卒中恢复生物标志物。
  • 共识覆盖卒中后恢复时间线上运动、感觉、认知和语言域,聚焦脑结构与功能,排除血液标志物和遗传学。

主要发现

  • 共识识别了被认为已可纳入临床试验的生物标志物。
  • 共识识别了有前景但尚未准备好纳入临床试验的生物标志物,并将其列为发展优先事项。
  • 通过一个示例说明生物标志物在恢复与康复研究中的效用,展示纳入标志物可能如何增强未来临床试验。

临床怎么用

  • 临床决策中可考虑使用已就绪的生物标志物区分卒中患者亚组,以指导康复内容与重点。
  • 研究设计时可纳入已就绪的生物标志物,减少高反应概率与低反应概率参与者的无意混合。
  • 对有前景但未成熟的标志物,应作为发展优先方向推进验证后再用于临床或试验。

局限性

  • 共识明确排除血液标志物和遗传学,未涵盖这些领域的证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The most difficult clinical questions in stroke rehabilitation are "What is this patient's potential for recovery?" and "What is the best rehabilitation strategy for this person, given her/his clinical profile?" Without answers to these questions, clinicians struggle to make decisions regarding the content and focus of therapy, and researchers design studies that inadvertently mix participants who have a high likelihood of responding with those who do not. Developing and implementing biomarkers that distinguish patient subgroups will help address these issues and unravel the factors important to the recovery process. The goal of the present paper is to provide a consensus statement regarding the current state of the evidence for stroke recovery biomarkers. Biomarkers of motor, somatosensory, cognitive and language domains across the recovery timeline post-stroke are considered; with focus on brain structure and function, and exclusion of blood markers and genetics. We provide evidence for biomarkers that are considered ready to be included in clinical trials, as well as others that are promising but not ready and so represent a developmental priority. We conclude with an example that illustrates the utility of biomarkers in recovery and rehabilitation research, demonstrating how the inclusion of a biomarker may enhance future clinical trials. In this way, we propose a way forward for when and where we can include biomarkers to advance the efficacy of the practice of, and research into, rehabilitation and recovery after stroke.

来源:Neurorehabil Neural Repair,查看原文。版权归原作者所有。

引用

  1. Boyd LA, Hayward KS, Ward NS, et al. Biomarkers of Stroke Recovery: Consensus-Based Core Recommendations from the Stroke Recovery and Rehabilitation Roundtable. Neurorehabil Neural Repair. 2017. PMID: 29233071. doi:10.1177/1545968317732680

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。